Skip to content

Albireo started at buy by Wedbush

June 30, 2017

Wedbush initiates coverage on Albireo Pharma (NASDAQ: ALBO) with a Outperform rating and a price target of $58.00.

Analyst Dr. Liana Moussatos is undervalued citing the Street reluctance to focus on recent clinical results expanding the market potential for the leading drug candidate A4250. Dr. Moussatos further comments “The lead product candidate is A4250 which is planned to start Phase 3 in H2:17, potentially launch in early 2021 and achieve sales of more than $1 billion in 2024.”

FY 2017 EPS estimate is for a loss of $3.70 and FY 2018 EPS estimate is for a loss of $4.03.

http://bit.ly/2tsLEi7

Advertisements

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: